Emilio Solano-Solares

Emilio Solano-Solares

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2017 in Journal of Investigational Allergology and Clinical Immunology
Verified
Journal Article
Open access
ESEmilio Solano-Solares
Emilio Solano-Solares
RMR Madrigal-Burgaleta
R Madrigal-Burgaleta
LCLv Carpio-Escalona
Lv Carpio-Escalona
LBL Bernal-Rubio
L Bernal-Rubio
MBMp Berges-Gimeno
Mp Berges-Gimeno
EAE Alvarez-Cuesta
E Alvarez-Cuesta
Key words: Chemotherapy, Desensitization, Drug allergy, Mastocytosis, Hypersensitivity

10 June 2023 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
NRNatalia Rodríguez-Otero
Natalia Rodríguez-Otero
JCJesús Chamorro-Pérez
Jesús Chamorro-Pérez
CFCarlos Fernández-Lozano
Carlos Fernández-Lozano
IEIsabel Elías-Sáenz
Isabel Elías-Sáenz
EBEmilio Berná-Rico
Emilio Berná-Rico
ESEmilio Solano-Solares
Emilio Solano-Solares

1 November 2020 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
RCR. Cabrera‐Hernández
R. Cabrera‐Hernández
ESEmilio Solano-Solares
Emilio Solano-Solares
VCV. Chica‐Guzmán
V. Chica‐Guzmán
MFM. Fernández‐Guarino
M. Fernández‐Guarino
DFD. Fernández‐Nieto
D. Fernández‐Nieto
BDB. De‐La‐Hoz‐Caballer
B. De‐La‐Hoz‐Caballer
Click on the article title to read more.

21 January 2022 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
MGMargarita Giraldo-Tugores
Margarita Giraldo-Tugores
CFCarlos Fernández-Lozano
Carlos Fernández-Lozano
ACAlejandra Carrón-Herrero
Alejandra Carrón-Herrero
PGPablo Gajate
Pablo Gajate
JMJavier Martinez-Botas
Javier Martinez-Botas
MBMaría Pilar Berges-Gimeno
María Pilar Berges-Gimeno

Verified
Journal Article
Open access
PDF file
CLCarlos Fernández Lozano
Carlos Fernández Lozano
ESEmilio Solano-Solares
Emilio Solano-Solares
IEIsabel Elías-Sáenz
Isabel Elías-Sáenz
IPIsabel Pérez-Allegue
Isabel Pérez-Allegue
Montserrat Fernández-GuarinoMontserrat Fernández-Guarino
Montserrat Fernández-Guarino
BHBelén de la Hoz
Belén de la Hoz
In the first wave of COVID-19, up to 20% of patients had skin lesions with variable characteristics. There is no clear evidence of the involvement of the SARS-CoV-2 virus in all cases; some of these lesions may be secondary to drug hypersensitivity. To analyze the possible cause of the skin lesions, we performed a complete allergology study on 11 patients. One year after recovery from COVID-19, we performed a lymphocyte transformation test (LTT) and Th1/Th2 cytokine secretion assays for PBMCs. We included five nonallergic patients treated with the same drugs without lesions. Except for one patient who had an immediate reaction to azithromycin, all patients had a positive LTT result for at least one of the drugs tested (azithromycin, clavulanic acid, hydroxychloroquine, lopinavir, and ritonavir). None of the nonallergic patients had a positive LTT result. We found mixed Th1/Th2 cytokine secretion (IL-4, IL-5, IL-13, and IFN-γ) in patients with skin lesions corresponding to mixed drug hypersensitivity type IVa and IVb. In all cases, we identified a candidate drug as the culprit for skin lesions during SARS-CoV-2 infection, although only three patients had a positive drug challenge. Therefore, it would be reasonable to recommend avoiding the drug in question in all cases.

21 November 2022 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
ABAlicia Barra-Castro
Alicia Barra-Castro
MBMaría Pilar Berges-Gimeno
María Pilar Berges-Gimeno
ACAlejandra Carrón-Herrero
Alejandra Carrón-Herrero
BABeatriz Arana-Fernández
Beatriz Arana-Fernández
ESEmilio Solano-Solares
Emilio Solano-Solares